A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia

NCT06368414 | Recruiting Phase 2

• 1 other identifier: KCMLWP-2021-04
• Study Type: interventional
• Target: 69
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the efficacy of asciminib adding on tyrosine-kinase inhibitors (TKI) to achieve treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients in chronic phase who failed prior cessation study of TKI

Conditions

Chronic Myeloid Leukemia, Chronic Phase

Outcome Measures

Primary Outcomes (1)

• MR3.0 or less by 1 year

  To evaluate the cumulative incidence of sustained MR3.0 or less by 1 year of cessation of TKI and asciminib

  by 1 year

Study Arms (1)

Asciminib arm

OTHER

Drug: Asciminib

Interventions

Asciminib DRUG

that patients who lost MR3.0 after stopping TKIs, thus failed to maintain treatment-free remission can achieve second sustainable MR4.5 by sustainable MR4.5 for more than 3 years once regained and prolong MRFS by adding asciminib to TKIs. Patients will be restarted on TKIs when they fail sustaining MR3.0 after cessation because restarting TKIs when loss of MR3.0 is reasonable in this situation

Asciminib arm

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• year or older
• CP-CML patients who are taking current TKIs (imatinib, nilotinib or dasatinib) for 5 years or more
• Patients who have failed maintaining MR3.0 after 1 or more cessation trial of TKIs.
• Patients who regained MR3.0 or deeper molecular response by TKIs retrial after TKI cessation failure at the time of screening
• Taking TKIs over 12 weeks for the retrial of TKIs after TKI cessation failure
• Patients who agree with stopping asciminib and TKIs after maintaining 23 year-duration of MR4.5
• Adequate end organ function as defined by:
• Total bilirubin (TBL) \< 3 x upper limit of normal (ULN); patients with Gilbert's syndrome may only be included if TBL ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN
• Creatinine clearance (ClCr) ≥ 30 mL/min as calculated using Cockcroft-Gault formula
• Serum lipase ≤ 1.5 x ULN. For serum lipase \> ULN - ≤ 1.5 x ULN, value must be considered not clinically significant and not associated with risk factors for acute pancreatitis
• Patients who can sign the informed consent of their own free will

You may not qualify if:

• Patients who experienced grade 3 or higher adverse events with TKIs (imatinib, dasatinib, and nilotinib).
• Patients who are receiving any other investigational agents.
• Patients who currently have uncontrolled infections
• Patients who previously received Chimeric antigen receptor T-cell (CAR-T cell) therapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) or biologic therapy.
• Patients with clinically significant cardiovascular disease or gastrointestinal dysfunction.
• Patients who have a history of thromboembolic episodes within 3 months prior to the study enrollment.
• Patients with active hepatitis B or C with uncontrolled disease activity.
• Patients who have active malignancies requiring treatment other than CML.
• Patients with any severe and/or uncontrolled medical conditions or other conditions that could adversely impact on patients' ability to participate in the study.
• Patients with psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant women are excluded from this study Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with asciminib and TKIs, breastfeeding should be discontinued if the mother is treated with asciminib and TKIs.

Sponsors & Collaborators

• Korean Society of Hematology: lead

Study Sites (1)

Gachon University Gil Medical Center

Incheon, Incheon, 21565, South Korea

RECRUITING

Related Publications (1)

• Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006 Aug 15;145(4):247-54. doi: 10.7326/0003-4819-145-4-200608150-00004.

  PMID: 16908915 BACKGROUND

MeSH Terms

Conditions

Leukemia, Myeloid, Chronic-Phase

Interventions

asciminib

Condition Hierarchy (Ancestors)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Myeloproliferative Disorders; Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Hawk Kim

  Korean Society of Hematology

  STUDY CHAIR

Central Study Contacts

Hawk Kim

CONTACT

82-10-8533-8019; ksh.cml.wp@gmail.com

Eunju Park

CONTACT

82-10-8533-8019; ksh.cmlwp.cra1@gmail.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 11, 2024
• First Posted: April 16, 2024
• Study Start: March 11, 2024
• Primary Completion (Estimated): August 31, 2028
• Study Completion (Estimated): August 31, 2028
• Last Updated: April 2, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)